Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Vertex Pharmaceuticals Incorporated keeps $19 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 11
in 84 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Vertex’s third fiscal quarter of 2026 came with revenue rising 11.8% to about $3.4 billion while adjusted EPS of $4.76 trailed the $4.82 estimate (-1.2%) and revenue of $3.441 billion came in line with the $3.419 billion consensus (+0.6%), based on preliminary results reported November 2, 2026. Results were driven by its cystic fibrosis medicines, including TRIKAFTA alongside KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI, sold across the U.S. and international markets. Profitability showed a gross margin of roughly 85% with gross profit of about $2.9 billion, while operating income was roughly $0.7 billion for an operating margin near 21%. Net income fell 39.6% year over year to about $0.7 billion, down from $1.083 billion a year ago, and adjusted EPS slipped 0.8% from $4.80. For the next period, consensus calls for EPS of $4.64 on revenue of $3.514 billion.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated develops and markets prescription medicines in biotechnology, centered on cystic fibrosis treatments and a broader genetic-disease pipeline. The NASDAQ-listed company generated $12.1 billion of revenue in FY2025. Its marketed portfolio includes TRIKAFTA for cystic fibrosis patients with at least one F508del mutation, along with KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI.
Today's Snapshot
VRTX ended the day slightly higher at 536.45, while its sector was weaker. Vertex Pharmaceuticals extended its drug-discovery deal with Genomics Limited, a research partner, worth $220 million.
Trading Volume
Below 10d avg (1.3M)
1.2M
vs S&P 500 Today
Outperforming Market
+0.68%
Updated: November 18, 2026 at 21:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$489.84 - $539.49Buy
- RSI (14)51.64Neutral
- Stochastic %K (14, 3, 3)27.55Neutral
- MACD Level (12, 26)5.10Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.